The article “Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease” reports on a phase I trial assessing the safety and efficacy of autologous MSCs in patients with refractory acute or chronic GVHD. The study found MSC therapy to be well tolerated with no dose-limiting toxicities. Responses were observed in both acute and chronic GVHD patients, with notable improvements in some cases. The trial supports MSCs as a safe treatment option, warranting further research for efficacy optimization.